School of Medicine


Showing 21-30 of 928 Results

  • Shuchi Anand

    Shuchi Anand

    Assistant Professor of Medicine (Nephrology) at the Stanford University Medical Center

    Current Research and Scholarly Interests Management of CKD and ESRD in low-resource settings
    Tubulointerstitial disease
    Chronic kidney disease of unknown etiology
    ESRD and physical activity
    ESRD and vitamin D deficiency

  • Chad Anderson

    Chad Anderson

    Clinical Assistant Professor, Medicine - Primary Care and Population Health

    Bio Chad Anderson is a Physician Assistant at Stanford ValleyCare and a Clinical Assistant Professor with the Stanford School of Medicine MSPA program. He is the Assistant Director of PA education at ValleyCare. He is dual credentialed as a Family Nurse Practitioner and a Physician Assistant. He completed his FNP/PA training at the Stanford School of Medicine and his graduate studies at A.T. Still University ? Arizona School of Health Sciences. He has great interest in improving patient care through process improvement and has been the lead in many successful projects. He is passionate about improving our patients hospital experience as well as educating our future providers. He is also interested in Pre-Hospital Care and Emergency Medicine.

  • Jason Andrews

    Jason Andrews

    Associate Professor of Medicine (Infectious Diseases)

    Current Research and Scholarly Interests Our laboratory aims to develop and test innovative approaches to the diagnosis, treatment and control of infectious diseases in resource-limited settings. We draw upon multiple fields including mathematical modeling, microbial genetics, field epidemiology, statistical inference and biodesign to work on challenging problems in infectious diseases, with an emphasis on tuberculosis and tropical diseases.

  • Justin P. Annes M.D., Ph.D.

    Justin P. Annes M.D., Ph.D.

    Associate Professor of Medicine (Endocrinology)

    Current Research and Scholarly Interests The ANNES LABORATORY of Molecular Endocrinology: Leveraging Chemical Biology to Treat Endocrine Disorders

    DIABETES
    The prevalence of diabetes is increasing at a staggering rate. By the year 2050 an astounding 25% of Americans will be diabetic. The goal of my research is to uncover therapeutic strategies to stymie the ensuing diabetes epidemic. To achieve this goal we have developed a variety of innovate experimental approaches to uncover novel approaches to curing diabetes.

    (1) Beta-Cell Regeneration: Diabetes results from either an absolute or relative deficiency in insulin production. Our therapeutic strategy is to stimulate the regeneration of insulin-producing beta-cells to enhance an individual?s insulin secretion capacity. We have developed a unique high-throughput chemical screening platform which we use to identify small molecules that promote beta-cell growth. This work has led to the identification of key molecular pathways (therapeutic targets) and candidate drugs that promote the growth and regeneration of islet beta-cells. Our goal is to utilize these discoveries to treat and prevent diabetes.

    (2) The Metabolic Syndrome: A major cause of the diabetes epidemic is the rise in obesity which leads to a cluster of diabetes- and cardiovascular disease-related metabolic abnormalities that shorten life expectancy. These physiologic aberrations are collectively termed the Metabolic Syndrome (MS). My laboratory has developed an original in vivo screening platform t to identify novel hormones that influence the behaviors (excess caloric consumption, deficient exercise and disrupted sleep-wake cycles) and the metabolic abnormalities caused by obesity. We aim to manipulate these hormone levels to prevent the development and detrimental consequences of the MS.

    HEREDIATY PARAGAGLIOMA SYNDROME
    The Hereditary Paraganglioma Syndrome (hPGL) is a rare genetic cancer syndrome that is most commonly caused by a defect in mitochondrial metabolism. Our goal is to understand how altered cellular metabolism leads to the development of cancer. Although hPGL is uncommon, it serves as an excellent model for the abnormal metabolic behavior displayed by nearly all cancers. Our goal is to develop novel therapeutic strategies that target the abnormal behavior of cancer cells. In the laboratory we have developed hPGL mouse models and use high throughput chemical screening to identify the therapeutic susceptibilities that result from the abnormal metabolic behavior of cancer cells.

    As a physician scientist trained in clinical genetics I have developed expertise in hereditary endocrine disorders and devoted my efforts to treating families affected by the hPGL syndrome. By leveraging our laboratory expertise in the hPGL syndrome, our care for individuals who have inherited the hPGL syndrome is at the forefront of medicine. Our goal is to translate our laboratory discoveries to the treatment of affected families.

  • Sally Arai

    Sally Arai

    Associate Professor of Medicine (Blood and Marrow Transplantation) at the Stanford University Medical Center

    Current Research and Scholarly Interests Research interest in utilizing post-transplant adoptive cellular immunotherapy to reduce GVHD and relapse in patients with high risk hematologic malignancies.

  • Danit Ariel

    Danit Ariel

    Clinical Assistant Professor, Medicine - Endocrinology, Gerontology, & Metabolism

    Bio Danit Ariel, MD MS, is double board certified in Internal Medicine and Endocrinology. Dr. Ariel graduated from UC Davis School of Medicine. She then completed a residency in Internal Medicine at Stanford and a fellowship and post-doctorate in Endocrinology and Metabolism at Stanford before joining the faculty at Stanford.

    Dr. Ariel practices general endocrinology, with a special interest in thyroid disorders, menopause, LGBTQ+ health, and transgender medicine amongst others.

    She believes in practicing compassionate care: in listening to her patients? concerns, respecting their values, communicating well, and providing an evidence-based approach to help guide individualized treatment plans. She is deeply committed to utilizing her expertise in the field of endocrinology to optimize her patients? health and well-being.

    Dr. Ariel is passionate about medical education and teaching, and serves on the teaching faculty in the Stanford University School of Medicine. She completed an honors certificate in medical education from Stanford. She is the Founding Director of the Student Guidance Program for medical students. Finally, within the division of Endocrinology, she is the Director of Faculty Wellness.

    Appointments with with Dr. Ariel are available in the Hoover Pavilion on 211 Quarry Road.

Footer Links:

Stanford Medicine Resources: